A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer.
A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer.
复制标题
DOI：
10.1016/j.ebiom.2021.103481
复制
发表时间：
2021-07
期刊：
影响因子：
11.1
通讯作者：
Madabhushi A
中科院分区：
文献类型：
--
作者：
Wang X;Bera K;Barrera C;Zhou Y;Lu C;Vaidya P;Fu P;Yang M;Schmid RA;Berezowska S;Choi H;Velcheti V;Madabhushi A
海报展示在USCAP第108届年会，2019年3月16日至21日。我们使用来自早期非小细胞肺癌（ES-NSCLC）患者的H&E染色组织图像开发并验证了预后和预测性计算病理学风险评分（CoRiS）。从3个独立来源获得1330例ES-NSCLC患者，并将其分为4个队列D1-4。D1包括100例手术治疗的患者，并用于通过弹性网络考克斯模型确定预后特征，以预测总生存期和无病生存期。CoRiS使用顶部特征的考克斯模型系数构建。在D2（N=331）、D3（N=657）和D4（N=242）评价了CoRiS的预后性能。通过比较不同CoRiS定义的风险组之间的生存率，使用D2和D3（包括手术+化疗）的患者来验证CoRiS是否可预测辅助化疗（ACT）的额外获益。在单变量分析中，发现CoRiS具有预后性，D2（风险比（HR）= 1.41，校正（adj.）P = 0.01）和D3（HR = 1.35，adj. P <0.001）。多变量分析显示，在调整临床病理因素后，CoRiS是独立的预后因素，D2（HR = 1.41，adj. P < .001）和D3（HR = 1.35，adj. P < .001）。CoRiS还能够识别从ACT D2（HR = 0.42，adj. P = 0.006）和D3（HR = 0.46，adj. P = 0.08）中获得生存获益的高风险患者。CoRiS是一种组织非破坏性，定量和低成本的工具，可能有助于指导ES-NSCLC患者的管理。
Poster presentation at the USCAP 108th Annual Meeting, March 16–21, 2019. We developed and validated a prognostic and predictive computational pathology risk score (CoRiS) using H&E stained tissue images from patients with early-stage non-small cell lung cancer (ES-NSCLC). 1330 patients with ES-NSCLC were acquired from 3 independent sources and divided into four cohorts D1-4. D1 comprised 100 surgery treated patients and was used to identify prognostic features via an elastic-net Cox model to predict overall and disease-free survival. CoRiS was constructed using the Cox model coefficients for the top features. The prognostic performance of CoRiS was evaluated on D2 (N=331), D3 (N=657) and D4 (N=242). Patients from D2 and D3 which comprised surgery + chemotherapy were used to validate CoRiS as predictive of added benefit to adjuvant chemotherapy (ACT) by comparing survival between different CoRiS defined risk groups. CoRiS was found to be prognostic on univariable analysis, D2 (hazard ratio (HR) = 1.41, adjusted (adj.) P = .01) and D3 (HR = 1.35, adj. P < .001). Multivariable analysis showed CoRiS was independently prognostic, D2 (HR = 1.41, adj. P < .001) and D3 (HR = 1.35, adj. P < .001), after adjusting for clinico-pathologic factors. CoRiS was also able to identify high-risk patients who derived survival benefit from ACT D2 (HR = 0.42, adj. P = .006) and D3 (HR = 0.46, adj. P = .08). CoRiS is a tissue non-destructive, quantitative and low-cost tool that could potentially help guide management of ES-NSCLC patients.
登录
查看更多内容
DOI：
10.1097/jto.0000000000000365
发表时间：
2015-01
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Bueno R;Hughes E;Wagner S;Gutin AS;Lanchbury JS;Zheng Y;Archer MA;Gustafson C;Jones JT;Rushton K;Saam J;Kim E;Barberis M;Wistuba I;Wenstrup RJ;Wallace WA;Hartman AR;Harrison DJ
通讯作者：
Harrison DJ
影响因子：
2.4
作者：
Leo, Patrick;Lee, George;Madabhushi, Anant
通讯作者：
Madabhushi, Anant
空间结构和肿瘤浸润淋巴细胞的排列，以预测早期非小细胞肺癌中复发的可能性。
DOI：
10.1158/1078-0432.ccr-18-2013
发表时间：
2019-03-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Corredor G;Wang X;Zhou Y;Lu C;Fu P;Syrigos K;Rimm DL;Yang M;Romero E;Schalper KA;Velcheti V;Madabhushi A
通讯作者：
Madabhushi A
DOI：
10.1038/s41374-018-0095-7
发表时间：
2018-11
期刊：
Laboratory investigation; a journal of technical methods and pathology
影响因子：
--
作者：
Lu C;Romo-Bucheli D;Wang X;Janowczyk A;Ganesan S;Gilmore H;Rimm D;Madabhushi A
通讯作者：
Madabhushi A
影响因子：
45.3
作者：
Endoh, H;Tomida, S;Mitsudomi, T
通讯作者：
Mitsudomi, T